In This Section

Pharmacology Perspectives on Attaining Diversity, Equity and Inclusion in Clinical Trials

Saturday April 02, 2022

1:30 pm - 3:00 pm Central Time (CT)

114 Nutter Auditorium


Chair :

Deborah Luessen
Vanderbilt University

Pamela Hornby

This symposium aims to increase awareness of the ongoing and pervasive issues surrounding inequality in clinical trial development and provide insights on how these factors impact the validity and use of clinical trial results that currently perpetuate health disparities. This symposium will highlight the pharmacological insights and novel strategies to diversify scientific approaches involved in pharmacotherapeutic clinical trial design, execution and outcome analysis to overcome barriers for patients from underrepresented populations. The symposium will provide unique perspectives from leaders in the field of pharmacology representing a broad range of disciplines (industry, academia, government). The speakers have been selected based on their alignment with pharmacological scientific approaches and will present on topics of interest to a broad group of preclinical and clinical pharmacologists.


Jorge Hechavarria - Janssen

J&J Diversity and Inclusion in Clinical Trials with Highlights from ENSEMBLE (COVID-19 Vaccine)

Dr. Hargraves is Vice President of R&D Portfolio Management at Janssen. Dr. Hargraves will speak about current efforts for educating and enrolling diverse populations in clinical trial and will discuss recent highlights pertaining to diversity in the recent ENSEMBLE COVID vaccine trial.

Sapna McManus - Genentech

Ensuring that Patients of Color have Access to Clinical Trials: Diversity in Drug Discovery Genomic Databanks

Dr. Sapna McManus is a Medical Affairs Executive Director at Genentech. She discusses ongoing initiatives that she is involved in to develop external partnering strategies to address health equity issues and ensure patients of color have access to clinical trials and quality care by Advancing Inclusive Research.

Richardae Araojo - CDER/FDA

FDA Efforts to Advance Racial and Ethnic Minority Participation in Clinicals Trials

Dr Richardae Araojo serves as the Associate Commissioner for Minority Health and Director of the Office of Minority Health and Health Equity (OMHHE) in the Office of the Commissioner at the U.S. Food and Drug Administration (FDA). In this role, RADM Araojo provides leadership, oversight, and direction on minority health and health disparity matters for the Agency. Certain populations are less accepting of generics, but this is changing due to generic drug landscape and insurance coverage. How do we ensure that the product is bioequivalent for all populations?

Round-table Q&A Session

Last Updated: March 27, 2022
Key Dates

Thank you to our Annual Meeting partners: